Ryan D. Maynard
2016
In 2016, Ryan D. Maynard earned a total compensation of $1.1M as Executive Vice President, Chief Financial Officer at Rigel Pharmaceuticals, a 1% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $147,740 |
---|---|
Option Awards | $493,380 |
Salary | $454,585 |
Other | $1,170 |
Total | $1,096,875 |
Maynard received $493.4K in option awards, accounting for 45% of the total pay in 2016.
Maynard also received $147.7K in non-equity incentive plan, $454.6K in salary and $1.2K in other compensation.
Rankings
In 2016, Ryan D. Maynard's compensation ranked 7,792nd out of 14,075 executives tracked by ExecPay. In other words, Maynard earned more than 44.6% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 7,792 out of 14,075 | 45th |
Division Manufacturing | 2,964 out of 5,489 | 46th |
Major group Chemicals And Allied Products | 983 out of 1,895 | 48th |
Industry group Drugs | 762 out of 1,538 | 51st |
Industry Pharmaceutical Preparations | 607 out of 1,176 | 48th |
Source: SEC filing on March 29, 2017.
Maynard's colleagues
We found four more compensation records of executives who worked with Ryan D. Maynard at Rigel Pharmaceuticals in 2016.